Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 12,100 shares, a decrease of 50.4% from the June 30th total of 24,400 shares. Based on an average trading volume of 151,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A hedge fund recently raised its stake in Hepion Pharmaceuticals stock. Armistice Capital LLC grew its stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 418,000 shares of the company’s stock after purchasing an additional 20,393 shares during the quarter. Armistice Capital LLC owned approximately 9.63% of Hepion Pharmaceuticals worth $1,354,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Price Performance

NASDAQ HEPA traded up $0.03 on Friday, hitting $0.80. 93,050 shares of the stock were exchanged, compared to its average volume of 108,960. The business’s fifty day moving average is $1.07 and its 200 day moving average is $1.74. Hepion Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $8.31. The company has a market capitalization of $4.61 million, a PE ratio of -0.09 and a beta of 1.85.

Hepion Pharmaceuticals (NASDAQ:HEPA) last issued its quarterly earnings data on Tuesday, May 21st. The company reported ($0.56) earnings per share for the quarter.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.